IMPROVED SLEEP
NEMLUVIO is proven to significantly improve sleep for patients with PN1
SLEEP DISTURBANCE NUMERICAL RATING SCALE (SD-NRS)3,4
- Patient-reported outcome used to evaluate degree of sleep loss the previous night
- Treatment success defined as at least a 4-point improvement from baseline
of adults with PN reported sleep disturbance as a negative impact of PN on their quality of life5
Actor portrayal.
Q4W Dosing From the Start6
NEMLUVIO offers the convenience of less frequent dosing compared to the other biologic for PN6,7
Favorable Safety Profile6
NEMLUVIO offers a favorable safety profile and requires no preliminary lab evaluations or ongoing lab monitoring6
Sign up now for more information about NEMLUVIO and PN
PN=prurigo nodularis; SD-NRS=Sleep Disturbance Numerical Rating Scale; Q4W=every 4 weeks.
References: 1. Galderma Laboratories, L.P.; data on file. Clinical Study Report RD.06.SRE.203065; September 2023. 2. Galderma Laboratories, L.P.; data on file. Clinical Study Report RD.06.SRE.202685; September 2023. 3. Kwatra SG, Misery L, Clibborn C, Steinhoff M. Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics. Clin Transl Immunology. 2022;11(5):e1390. doi:10.1002/cti2.1390 4. Stander S, Fofana F, Dias-Barbosa C, et al. The Sleep Disturbance Numerical Rating Scale: content validity, psychometric validation, and meaningful within-patient change in prurigo nodularis. Dermatol Ther (Heidelb). 2023;13(7):1587-1602. doi:10.1007/13555-023-00962-8 5. Rodriguez D, Kwatra SG, Dias-Barbosa C, et al. Patient perspectives on living with severe prurigo nodularis. JAMA Dermatol. 2023;159(11):1205-1212. doi:10.1001/jamadermatol.2023.3251 6. NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P.; August 2024. 7. DUPIXENT. Prescribing information. Sanofi Genzyme; 2024.